Castle BiosciencesCSTL -1.33%73 Net Current Asset Value is $8.00 as of Mar. 2026, which is 172% above its 10-year median of 2.94. GuruFocus rates CSTL with a GF Score™ of 73/100 and a GF Value™ of $29.18 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 98 Medical Diagnostics & Research companies, Castle Biosciences ranks better than 63.27% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Castle Biosciences's net current asset value per share for the quarter that ended in Mar. 2026 was $8.00.
The historical rank and industry rank for Castle Biosciences's Net Current Asset Value or its related term are showing as below:
CSTL'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.65 Med: 2.94 Max: 7.18
Current: 3.05
During the past 9 years, the highest Price-to-Net-Current-Asset-Value Ratio of Castle Biosciences was 7.18. The lowest was 1.65. And the median was 2.94.
CSTL's Price-to-Net-Current-Asset-Value is ranked better than 63.27% of 98
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.96
vs CSTL: 3.05
Castle Biosciences (NAS:CSTL) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Castle Biosciences Net Current Asset Value Related Terms
Castle Biosciences Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Castle Biosciences's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSTL vs FLGT, MYGN, OPK: Net Current Asset Value Comparison
For the Diagnostics & Research subindustry, Castle Biosciences's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Castle Biosciences Price-to-Net-Current-Asset-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Castle Biosciences's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $8.00 mean?
Castle Biosciences (CSTL) has a Net Current Asset Value of $8.00 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Castle Biosciences and its competitors. This is 172% above median its historical median of 2.94. Over the past decade, Castle Biosciences' Net Current Asset Value has ranged from 1.65 to 7.18. According to the industry distribution chart, Castle Biosciences ranks #36 out of 98 companies in the Medical Diagnostics & Research industry, placing it in the top 36.7%.
Is Castle Biosciences' Net Current Asset Value too high?
Castle Biosciences' current Net Current Asset Value of $8.00 is 172% above median its 10-year median of 2.94. Over the past 10 years, this metric has ranged from a low of 1.65 to a high of 7.18. The Medical Diagnostics & Research industry median Net Current Asset Value is 3.96. Castle Biosciences' value of $8.00 is 102% above this industry median. Based on the distribution chart, Castle Biosciences ranks #36 out of 98 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Castle Biosciences has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Net Current Asset Value compare to FLGT and MYGN?
According to the Medical Diagnostics & Research industry distribution chart, Castle Biosciences ranks #36 out of 98 companies for Net Current Asset Value. This puts Castle Biosciences in the upper half of its industry. The industry median Net Current Asset Value is 3.96. Castle Biosciences' value of $8.00 is 102% above this benchmark. Historically, Castle Biosciences' own Net Current Asset Value has ranged from 1.65 to 7.18 over the past decade. While the company's 10-year median is 2.94 vs. the industry median of 3.96, Castle Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Diagnostics & Research company?
The median Net Current Asset Value among Medical Diagnostics & Research companies is 3.96, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Castle Biosciences's current Net Current Asset Value of $8.00 is 102% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Castle Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median Net Current Asset Value is 3.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Castle Biosciences's current Net Current Asset Value is $8.00, which is 172% above median its own 10-year median of 2.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.18, compared to a current price of $24.39 — trading 16.4% below its estimated fair value. The current Net Current Asset Value is $8.00, which is 172% above median its 10-year median of 2.94 and 102% above the Medical Diagnostics & Research industry median of 3.96. Castle Biosciences' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Net Current Asset Value is $8.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Castle Biosciences (CSTL) Overvalued in 2026?
Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued.
The current stock price of $24.39 is trading 16.4% below its estimated GF Value™ of $29.18.
GuruFocus considers Castle Biosciences to be Modestly Undervalued.
Key valuation signals for CSTL:
Net Current Asset Value: $8.00 (172% above median its 10-year median of 2.94)
GF Value™: $29.18 vs. price of $24.39 (16.4% below fair value)
Industry Position: 102% above the Medical Diagnostics & Research median (#36 of 98)
No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
73GF Score
Get the complete analysis for CSTL
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSTL has been successfully added to your 
